Your browser doesn't support javascript.
loading
The use of recovery animals in nonclinical safety assessment studies with monoclonal antibodies: further 3Rs opportunities remain.
Prior, Helen; Andrews, Laura; Cauvin, Annick; Chien, Hsiaotzu; Clarke, David O; Datta, Kaushik; Dempster, Maggie; Dybdal, Noel; Freebern, Wendy; de Haan, Lolke; Herzyk, Danuta; Hey, Adam; Kissner, Thomas; Kronenberg, Sven; Leach, Michael W; Lee, Donna; Reid, Kirsty; Schutte, Katrin; Sewell, Fiona; Trouba, Kevin; Ulrich, Peter; van Aerts, Leon; van Meer, Peter; Weir, Lucinda.
Affiliation
  • Prior H; National Centre for the Replacement Refinement & Reduction of Animals in Research (NC3Rs), London, UK. Electronic address: helen.prior@nc3rs.org.uk.
  • Andrews L; AbbVie, Worcester, MA, USA.
  • Cauvin A; UCB BioPharma, Brussels, Belgium.
  • Chien H; Medicine Evaluation Board, Utrecht, the Netherlands.
  • Clarke DO; Lilly Corporate Center, Indianapolis, IN, USA.
  • Datta K; Bristol Myers Squibb, Nonclinical Research and Development, New Jersey, USA.
  • Dempster M; GlaxoSmithKline, King of Prussia, PA, USA.
  • Dybdal N; Genentech, South San Francisco, CA, USA.
  • Freebern W; Janssen Inc., Spring House, PA, USA.
  • de Haan L; ADC Therapeutics, I-HUB, Imperial College White City Campus, London, UK.
  • Herzyk D; Merck & Co., Inc., West Point, PA, USA.
  • Hey A; AstraZeneca, Cambridge, UK.
  • Kissner T; Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • Kronenberg S; Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Switzerland.
  • Leach MW; Pfizer Inc., Cambridge, MA, USA.
  • Lee D; Genentech, South San Francisco, CA, USA.
  • Reid K; European Federation of Pharmaceutical Industries and Associations, Brussels, Belgium.
  • Schutte K; European Commission, Brussels, Belgium.
  • Sewell F; National Centre for the Replacement Refinement & Reduction of Animals in Research (NC3Rs), London, UK.
  • Trouba K; Janssen Inc., Spring House, PA, USA.
  • Ulrich P; Novartis Institutes for BioMedical Research, Basel, Switzerland.
  • van Aerts L; Medicine Evaluation Board, Utrecht, the Netherlands.
  • van Meer P; Medicine Evaluation Board, Utrecht, the Netherlands.
  • Weir L; GlaxoSmithKline, Ware, Hertfordshire, UK.
Regul Toxicol Pharmacol ; 138: 105339, 2023 Feb.
Article in En | MEDLINE | ID: mdl-36649820
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Regul Toxicol Pharmacol Year: 2023 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Research Design / Antibodies, Monoclonal Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Regul Toxicol Pharmacol Year: 2023 Type: Article